What are the significant drug interactions of mycophenolate (mycophenolic acid) and how should they be managed?

Mycophenolate Drug Interactions

Mycophenolate has multiple clinically significant drug interactions that require careful medication review and timing adjustments, with the most critical being reduced absorption from antacids, proton pump inhibitors, and bile acid sequestrants, as well as dangerous bone marrow suppression when combined with azathioprine.

Critical Drug Interactions Requiring Avoidance

Azathioprine

• Concomitant use with azathioprine must be avoided 1, 2
• Combined use causes increased inhibition of purine metabolism and severe bone marrow suppression
• This is a contraindication to concurrent therapy

Live Vaccines

• Live attenuated vaccines should be avoided during mycophenolate therapy 1
• Patients may have inadequate immunologic response to vaccination

Major Interactions Requiring Dose Separation or Monitoring

Antacids and Phosphate Binders

Administer these agents at least 2 hours after mycophenolate 2:

• Activated charcoal
• Aluminum or magnesium hydroxide-containing antacids
• Calcium-free phosphate binders (e.g., sevelamer)
• Iron supplements

These agents inhibit mycophenolic acid (MPA) absorption from the GI tract, reducing efficacy 1.

Bile Acid Sequestrants

Separate administration by at least 1 hour before or 4-6 hours after mycophenolate 3:

• Cholestyramine
• Colestipol
• Colesevelam

These directly bind mycophenolic acid, significantly reducing absorption 3. A 3-hour separation window is adequate to avoid binding interactions 3.

Proton Pump Inhibitors (PPIs)

Monitor patients closely for reduced efficacy when PPIs are co-administered 2, 4, 5:

• PPIs (lansoprazole, pantoprazole, others) decrease MPA systemic exposure by reducing dissolution in higher pH environments 2, 4
• Meta-analysis shows PPIs significantly decrease MPA trough concentrations (mean difference -0.62 mg/L) and maximum concentrations (mean difference -4.71 mg/L) 5
• This interaction is primarily significant with mycophenolate mofetil, not enteric-coated mycophenolate sodium 4, 5
• Consider therapeutic drug monitoring or switching to enteric-coated formulation if PPI therapy is necessary

Drugs Interfering with Enterohepatic Recirculation

Monitor for reduced efficacy with these agents 2:

• Trimethoprim/sulfamethoxazole
• Rifampin (causes >2-fold reduction in MPA exposure through UGT induction) 6, 7
• Aminoglycosides, cephalosporins, fluoroquinolones, penicillins

These alter gastrointestinal flora or directly interfere with enterohepatic recirculation, decreasing MPA exposure 1, 2.

Drugs Modulating Glucuronidation

• Telmisartan (induces glucuronidation): Decreases MPA exposure; monitor for reduced efficacy 2
• Isavuconazole (inhibits glucuronidation): Increases MPA exposure; monitor for toxicity 2

Interactions Affecting Other Drugs

Drugs Undergoing Renal Tubular Secretion

Monitor for increased toxicity of these drugs, especially in renal impairment 2:

• Acyclovir/valacyclovir
• Ganciclovir/valganciclovir
• Probenecid

Mycophenolate's metabolite (MPAG) competes for renal tubular secretion, increasing plasma concentrations of these drugs 1, 2.

Hormonal Contraceptives

Use additional barrier contraceptive methods 2:

• Mycophenolate decreases levonorgestrel exposure (though not ethinylestradiol) 2
• This may reduce oral contraceptive effectiveness
• Critical given mycophenolate's teratogenic effects (FDA black box warning for pregnancy) 1

Calcineurin Inhibitor Interactions

Cyclosporine vs. Tacrolimus

• Tacrolimus co-administration increases MPA trough levels by approximately 80% (3.4 vs 1.87 μg/mL) compared to cyclosporine 8
• Consider lower MMF doses when using tacrolimus versus cyclosporine
• Therapeutic drug monitoring of MPA levels is advisable with either combination 8, 9

Management Algorithm

1. Before initiating mycophenolate:

   • Review all concurrent medications
   • Identify and discontinue azathioprine if present
   • Screen for drugs requiring dose separation or monitoring

2. For absorption-reducing agents:

   • Separate antacids/phosphate binders by ≥2 hours after mycophenolate
   • Separate bile acid sequestrants by 1 hour before or 4-6 hours after
   • Consider enteric-coated formulation if chronic PPI therapy needed

3. For drugs affecting MPA metabolism:

   • Monitor MPA trough levels when starting/stopping rifampin, telmisartan, or isavuconazole
   • Adjust mycophenolate dose based on therapeutic drug monitoring

4. For contraception:

   • Mandate additional barrier methods in all women of childbearing potential
   • Continue for 6 weeks after mycophenolate discontinuation

5. For renal impairment:

   • Exercise heightened caution with acyclovir/ganciclovir co-administration
   • Monitor for increased toxicity of renally secreted drugs

Common Pitfalls

• Failing to separate administration times with antacids or bile acid sequestrants leads to treatment failure
• Not recognizing the PPI interaction can result in subtherapeutic MPA levels and acute rejection
• Overlooking the azathioprine interaction risks life-threatening bone marrow suppression
• Inadequate contraceptive counseling given reduced hormonal contraceptive efficacy
• Not adjusting for calcineurin inhibitor choice (tacrolimus increases MPA levels significantly)